[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-subjects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-subjects":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,45,75,102,125,148,172,194,213,237,263,284,305,333,356,378,399,423,462,486,510,532,557,580,602],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100241170","prospective-evaluation-of-next-generation-ct-reconstruction-nextgenir-100241170",false,"NCT02417714","Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)","Prospective Evaluation of Next Generation CT Reconstruction","* INCLUSION CRITERIA:\n\nInclusion Criteria for Body CT:\n\n1. Clinical indication for a chest, abdomen and pelvis CT with contrast\n2. Age equal to or greater than 18 years\n3. Able to understand and willing to sign the Informed Consent Form\n\nInclusion Criteria for Chest CT:\n\n1. Clinical indication for a CT with or without contrast that includes the chest\n2. Age equal to or greater than 18 years\n3. Able to understand and willing to sign the Informed Consent Form\n\nEXCLUSION CRITERIA:\n\nExclusion Criteria for Body CT:\n\n1. Pregnancy\n2. Serum Cr \\> 1.5 mg\u002FdL\n3. Clinical CT scan with more than one contrast imaging phase (for example three phase liver)\n\nExclusion Criteria for Chest CT\n\n1\\. Pregnancy","ALL","18 Years","99 Years",{"count":21,"type":22},215,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Computed Tomography (CT) is a scan that makes detailed pictures of the body. It uses radiation to do that. In 2011, about 85.3 million CT scans were done in the United States. But there is growing concern about the health effects of radiation. There are new and different ways to make CT pictures that use less radiation. Researchers want to learn whether these new methods create images that are similar to images from a traditional CT.\n\nObjective:\n\n\\- To learn if new CT imaging methods with less radiation make images that are similar to traditional ways.\n\nEligibility:\n\n\\- Adults 18 years of age and older who are scheduled for a CT of the chest, abdomen and pelvis with contrast.\n\nDesign:\n\n* Researchers will review participants medical records to see if they can be in this study.\n* Participants may have blood drawn from an arm vein by a needle stick. The blood will be used to make sure they can be in this study and that it is safe for them to have contrast.\n* During the participants CT scan appointment, one extra scan will be done using low radiation methods.\n* During a CT scan, the participant lies on a table. A large x-ray machine takes pictures of the body.",[26],"Healthy Subjects",[28,29,30,31],"Computed Tomography","Radiation Reduction","Iterative Reconstruction","Natural History","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2014-09-08",{"date":40,"type":22},"2026-07-01",{"name":42,"class":43},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":4,"leadSponsor":73,"locationsCount":44},"100176270","oral-bacteria-and-immune-system-problems-involved-in-gum-disease-periodontitis-100176270","NCT01568697","Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)","Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction","* INCLUSION CRITERIA:\n\nSubjects with Genetic Immune Defects:\n\nPatients with a known genetic immune defect will be eligible for screening inclusion under this protocol.\n\n* Diagnosed with a genetic immune defect\n* Willing to allow genetic testing\n\n  * 7 years old\n\nSubjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n* History of severe periodontitis prior to age \\\u003C30\n* Willing to allow genetic testing\n\n  -\\>=7 years old\n* In good general health\n\nFamily members of Subjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n-Willing to allow genetic testing\n\n-\\>=7 years old\n\nHealthy Volunteer Subjects (with\u002Fwithout periodontitis):\n\n* In good general health\n\n  -\\>=18 years old\n* Willing to allow genetic testing\n* Have a minimum of 20 natural teeth\n\nInclusion Criteria for Natural History phase, all subjects:\n\n* Diagnosis of genetic immune defect\n* Presence of oral manifestation (primarily periodontitis)\n\nCriteria for standard of care treatment:\n\n* Active untreated disease (visible signs of tissue inflammation including erythema\u002Fedema, generalized bleeding upon probing)\n* Periodontal disease defined as bone loss of \\>=5mm as measured on periodontal exam.\n\nEXCLUSION CRITERIA:\n\nAll Subjects:\n\n* History of Hepatitis B or C\n* History of HIV\n* Prior radiation therapy to the head or neck\n* Have an active malignancy except localized basal or squamous cell carcinoma of the skin\n* Have been treated with systemic chemotherapeutics or radiation therapy within 5 years of screening\n* Pregnant or lactating\n* If participation in the protocol would not be safe or in the subject s best interest in the opinion of either the PI or the primary medical team.\n\nAdditional Exclusions for Healthy Volunteers:\n\n* Diagnosis of diabetes and\u002For HbA1C level \\>6%\n* More than 3 hospitalizations in the last 3years\n* Have an autoimmune disorder such as Lupus, Rheumatoid arthritis, etc.\n* In the 3 months before study enrollment, have used any of the following:\n\n  * Systemic (intravenous, intramuscular, or oral) antibiotics\n  * Oral, intravenous, intramuscular, intranasal, or inhaled corticosteroids or other immunosuppressants (e.g., cyclosporine)\n  * Cytokine therapy\n  * Methotrexate or immunosuppressive chemotherapeutic agents\n  * Large doses of commercial probiotics (\\>=10\\^8 colony-forming units or organisms per day); includes tablets, capsules, lozenges, chewing gum, or powders in which a probiotic is a primary component; ordinary dietary components such as fermented beverages\u002Fmilks, yogurts, and foods do not apply\n* Have used tobacco products (including e-cigarettes) within 1 year of screening\n* Unwillingness to consent to oral biopsy\n* NIH employees working in the Oral Immunity and Inflammation Unit and members of the Clinical Research Core Team will not be eligible for enrollment.\n\nAdditional Exclusions for Standard of Care Treatment at NIH:\n\n* Mild\u002Fmoderate non-active disease (absence of active inflammatory lesions)\n* Subjects with urgent\u002Fcomplex restorative needs (ex. severe active carious lesions\u002Ffractured dentition)\n* Subjects in need for advanced prosthetic needs (including implants and restorations)",true,"7 Years","100 Years",{"count":56,"type":22},700,"Background:\n\n\\- Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mouth.\n\nObjectives:\n\n\\- To study how immune system problems may lead to problems in the mouth, including gum disease.\n\nEligibility:\n\n* Children and adults at least 7 years of age who have genetic problems with their immune system.\n* Healthy adults that have periodontal disease\n* Health adults that do not have periodontal disease\n\nDesign:\n\n* This study will involve a screening visit and a study visit.\n* Participants will be screened with a medical history, blood work and a full oral and dental exam, including dental x-rays and photos.\n* The study visit will involve collection of blood, urine, and other samples, including saliva, plaque, and gum swabs. Any abnormal tissue will sampled for a biopsy. Additional oral and dental exams will be performed. Participants will also answer questions about any current medical or dental problems.",[59,60,26,61],"Immunosuppression","Periodontal Disease","Healthy Volunteer",[63,64,65,66,31,67,60,68,61,69],"Microbiome","Periodontitis","Oral Mucosal Immunity","Oral Infection","Immune Disorder","Gum Disease","HV",{"date":35,"type":36},{"date":72,"type":36},"2012-10-05",{"name":74,"class":43},"National Institute of Dental and Craniofacial Research (NIDCR)",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":52,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100623359","high-frequency-stimulation-to-improve-cognition-mobility-and-affect-in-individuals-with-and-without-subjective-cognitive-decline-100623359","NCT07395609","High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With and Without Subjective Cognitive Decline","Inclusion Criteria:\n\n* Community dwelling men and women 65-89 years old\n* Ability to walk unassisted for 10 min\n* English speaking\n\nAdditional Inclusion Criteria for SCD:\n\n* No evidence of dementia or MCI based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education, and sex using the NACC Uniform Data Set (UDS) norms8\n* Global Clinic Dementia Rating (CDR) score must be 0 or 0.531\n* Subjective report of cognitive complaints with scores \\>20 on the Cognitive Change Index (CCI-20), a validated scale of subjective cognitive decline6; this scale consists of 20 items that are rated on a 5-point Likert scale, where 1= \"Normal: No change compared to 5 years ago\", 3= \"Mild Problem: Some change compared to 5 years ago) and 5=\"Severe Problem: Much worse compared to 5 years ago\"\n* Family history of dementia\u002Fprobable AD in first degree relative (parents, children, siblings)\n* Normal functional behavior in terms of daily activities, based on the Functional Activities Scale32\n* In line with recommendations of the SCD task force33 an informant must be available for two reasons: a) to provide information about the participant's cognition using the informant version of the CDR and CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire32 (informant data will be collected via a phone call and linked by code with the participant data).\n\nExclusion Criteria:\n\n* If participants score less than 21 on the Telephone Interview for Cognitive Status (TICS)\n* Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.)\n* Severe visual impairment or corrected visual acuity less than 20\u002F40, which would preclude completion of assessments\n* Inability to undergo MRI brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, certain non-removable body jewelry, or shrapnel containing ferromagnetic metal\n* History of severe stroke\n* Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer)\n* Report of lower extremity pain due to osteoarthritis that significantly limits mobility\n* Diagnosis or treatment for rheumatoid arthritis\n* Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)\n* Unable to communicate because of severe hearing loss or speech disorder\n* Planned surgical procedure or hospitalization in the next 4 months (joint replacement, coronary artery bypass graft, etc.)\n* Severe pulmonary disease, requiring the use of supplemental oxygen\n* Terminal illness, as determined by a physician\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Use of walker or wheelchair","65 Years","89 Years",{"count":84,"type":22},60,"INTERVENTIONAL",[87],"NA","The goal is to determine whether three months of at least three times \u002F week of sensory flicker stimulation improves cognition, mobility, and affect in healthy older adults and older adults with and without Subjective Cognitive Decline (SCD). Investigators will also determine whether the intervention slows cortical thinning and declines in brain functional network segregation and changes in blood biomarkers of Alzheimer's Disease (AD).",[90,26],"Subjective Cognitive Decline (SCD)","NOT_YET_RECRUITING","2026-06-23",{"date":94,"type":36},"2026-06-26",{"date":96,"type":22},"2026-07",{"date":98,"type":22},"2028-10-31",{"name":100,"class":101},"University of Florida","OTHER",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100597543","bladder-and-bowel-functions-participation-and-quality-of-life-in-children-with-intellectual-disabilities-100597543","NCT07059858","Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities","Evaluation of Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities","Inclusion Criteria:\n\nFor Children with Intellectual Disabilities:\n\n* Aged between 5 and 12 years\n* Diagnosed with mild, moderate, or severe intellectual disability as documented by the ÇÖZGER (Child Special Needs Report)\n* Both the parent and the child agree to participate in the study\n\nFor Typically Developing Children\n\n* Aged between 5 and 12 years\n* Both the parent and the child agree to participate in the study\n\nExclusion Criteria:\n\nFor Children with Intellectual Disabilities:\n\n* Having a diagnosis of physical disability\n* Presence of a neurological anomaly affecting bladder and bowel functions\n* Parent does not consent to participate in the study\n* Having undergone trauma or surgery affecting bladder and bowel functions within the last 6 months\n* Diagnosis of a genetic disorder\n* Use of medications that may affect bladder and bowel functions\n\nFor Typically Developing Children\n\n* Presence of a neurological anomaly affecting bladder and bowel functions\n* Lack of parental consent to participate in the study\n* Having experienced trauma or undergone surgery affecting bladder and bowel functions within the past 6 months\n* Use of medications that may influence bladder and bowel functions","5 Years","12 Years",{"count":112,"type":22},100,"Many neurodevelopmental, psychiatric, and medical disorders are commonly associated with intellectual disability. The presence of neurodevelopmental and psychiatric (NDP) comorbidities has been reported to negatively impact the clinical outcomes of bowel or bladder dysfunction.\n\nPediatric bladder and bowel dysfunction (BBD) is a common but underdiagnosed condition characterized by a spectrum of lower urinary tract symptoms and is often associated with constipation. Lower urinary tract symptoms include dysuria, urinary urgency, daytime incontinence, and enuresis, while bowel symptoms include constipation and encopresis. Most BBD cases are functional and not neurogenic in origin.\n\nIn children with special needs, all types of urinary incontinence are reported to occur more frequently compared to children without developmental or behavioral disabilities. Intellectual disability (IQ \\\u003C70) is also identified as a significant risk factor for urinary incontinence, with prevalence increasing as IQ decreases. In these children, lower urinary tract symptoms such as overactive bladder, dysfunctional voiding, and low fluid intake are also observed. Furthermore, according to support plans and medical records, 94% of individuals with intellectual and multiple disabilities experience constipation. Interestingly, lower levels of intellectual disability (profound and severe ID) have been associated with a lower prevalence of constipation.\n\nAlthough there are studies in the literature examining bladder and bowel functions separately in specific diagnostic groups with intellectual disability, the number of studies that assess bladder and bowel functions together in children with any form of intellectual disability is limited. Moreover, to our knowledge, there is no study in the literature that evaluates bladder and bowel functions along with child participation and parental quality of life in children with intellectual disability.\n\nBased on this gap in the literature, the aim of our study is to examine bladder and bowel functions, participation, and quality of life in children with intellectual disability",[115,26],"Intellectual Disability","2026-06-16",{"date":118,"type":36},"2026-06-17",{"date":120,"type":36},"2025-09-28",{"date":122,"type":22},"2026-12-02",{"name":124,"class":101},"Abant Izzet Baysal University",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":52,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":85,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100624909","imaging-of-electrical-properties-by-mri-investigation-of-age-related-changes-100624909","NCT07415759","Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes","ELECTRA","Inclusion Criteria:\n\n* Person aged between 6 and 12, 20 and 40 years or aged 70 years and above\n* Person affiliated with a social security scheme or beneficiary of such a scheme\n* Person, or parent\u002Flegal guardian in the case of minors, who has received full information about the organization of the study and has signed the informed consent form\n\nExclusion Criteria:\n\n* Contraindication to undergoing an MRI examination or the presence of an MRI-incompatible medical device\n* Person presenting a pathology or tissue damage in the examined areas that may affect the measured MRI parameters\n* Pregnant woman, woman in labor, or breastfeeding mother\n* Person deprived of liberty by judicial or administrative decision, or persons undergoing psychiatric care","6 Years",{"count":134,"type":22},120,[87],"The goal of this study is to build a database of personalized EP (Electrical Properties) maps (accounting for age, anatomical location, and tissue complexity), obtained via MRI, to improve electromagnetic safety assessments, especially in the context of MRI. The EP values derived from this study are expected to be more accurate than current literature values, leading to more realistic specific absorption rate (SAR) modeling and improved patient safety. To investigate age-related differences, the study will include three distinct age groups.",[26],"2026-06-11",{"date":140,"type":36},"2026-06-12",{"date":142,"type":36},"2026-04-04",{"date":144,"type":22},"2029-02-02",{"name":146,"class":101},"Central Hospital, Nancy, France",2,{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":85,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":44},"100611540","phase-1-a-single-ascending-dose-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-syh2061-100611540","NCT07241910","A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061","A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2061 in Healthy Subjects","Inclusion Criteria:\n\n1. Subjects must be informed of the study before it begins, fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;\n2. Healthy male or female subjects, aged 18 to 55 years (inclusive);\n3. Body mass index ranging from 19.0 to 28.0 kg\u002Fm2 (inclusive), with a body weight of ≥ 50 kg for males and ≥ 45 kg for females;\n4. The results of various examinations, such as physical examination, vital signs, ECG, chest X-ray, abdominal B-scan ultrasound, and laboratory tests at screening are normal or abnormal without clinical significance;\n5. Vaccinated against meningococcal ACYW135 vaccine and pneumococcal vaccine at least 14 days prior to the first dose, or have valid documentation of receiving the respective vaccinations within the past 3 years prior to dosing as evaluated by the investigator.;\n6. Subjects and their partners agree to use effective and reliable contraceptive methods from 14 days before signing the ICF until 6 months after drug administration; male subjects agree not to donate sperm and female subjects agree not to donate ova from signing the ICF until 6 months after study drug administration;\n7. Subjects are able to communicate well with the investigator and can complete the study in accordance with the protocol.\n\nExclusion Criteria:\n\n1. History and\u002For current presence of clinically significant medical conditions, including but not limited to circulatory system disorders, hematological or hematopoietic system disorders, respiratory disorders, endocrine disorders, urinary system disorders, digestive system disorders, neurological or psychiatric disorders, autoimmune diseases, malignant tumors, severe trauma, or any other disease that should be excluded or may interfere with the interpretation of the study results in the opinion of the investigator;\n2. History of splenectomy, or functional or anatomical asplenia;\n3. Known or suspected hereditary or acquired complement deficiency or impaired complement activity, or complement activity below the normal range at screening;\n4. History of meningococcal infection, or positive Neisseria meningitides test at screening;\n5. Subjects who are frequently exposed to Neisseria meningitides (e.g., research, industrial, or clinical laboratory personnel, military personnel during recruit training, daycare center staff, etc.), and those who have traveled to or plan to travel to endemic areas for meningococcal meningitis (e.g., India, sub-Saharan Africa, Saudi Arabia) within 6 months before dosing or during the course of the study;\n6. History of recurrent or chronic infections (e.g., recurrent upper respiratory tract infection, diarrhoea, etc.) or infections requiring systemic antibiotic therapy within 3 months before dosing;\n7. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection including herpes, herpes zoster, or cold sores within 14 days before dosing;\n8. History or current presence of latent or active pulmonary tuberculosis, or positive T-SPOT test at screening;\n9. History of major surgery within 6 months prior to screening, or plan to undergo major surgery during the course of the study;\n10. Subjects with severe allergic diseases or allergic constitution (≥ 3 drug or food allergies), or a known history of allergy to the investigational drug components, oligonucleotide drugs, or vaccinations;\n11. Subjects who are allergic to β-lactam antibiotics (e.g., penicillin, cephalosporins) or ciprofloxacin, or have any contraindications, or unwilling to use antibiotic prophylaxis as specified in the protocol;\n12. Intolerance to subcutaneous injection, or presence of abdominal scars (from surgery, burns, etc.) that affect subcutaneous administration, and any skin abnormalities and\u002For tattoos that may affect the safety assessment of the injection site;\n13. Any of the following liver function test results: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), γ-glutamyl transferase (GGT), or alkaline phosphatase (ALP) above the upper limit of normal at screening;\n14. Estimated glomerular filtration rate (eGFR) \\\u003C 90 mL\u002Fmin\u002F1.73 m2 (calculated by the simplified MDRD formula) at screening;\n15. Prolonged QT\u002FQTc interval at screening or baseline (QTcF \\> 450 ms for males, \\> 470 ms for females);\n16. Positive result for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, human immunodeficiency virus (HIV) antigen\u002Fantibody, or Treponema pallidum antibody;\n17. Use of any prescription drugs, over-the-counter drugs, herbal medicines or vitamin and dietary supplements within 14 days or 5 half-lives (whichever is longer) before dosing;\n18. Received complement inhibitor treatment (e.g., Eculizumab, Crovalimab, etc.) within 6 months or 5 half-lives (whichever is longer) before dosing;\n19. Received live or live-attenuated vaccines within 28 days before dosing, or plan to receive such vaccines during the course of the study (except for vaccinations planned by the study protocol);\n20. Blood loss or blood donation of more than 200 mL within 3 months before screening (except for menstruation in females), or platelet donation within 2 weeks before screening;\n21. History of drug abuse, or use of illicit drugs within 3 months before screening, or habitual use of any psychotropic drugs (including herbal medicines), or a positive urine drug screen;\n22. Regular alcohol consumption within 6 months before screening, defined as weekly alcohol consumption exceeding 14 units (1 unit = 360 mL of 5% alcohol beer or 45 mL of 40% alcohol spirits or 150 mL of 12% alcohol wine), or inability to stop alcohol intake as required by the protocol during the study, or a positive blood alcohol test;\n23. Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months before screening, or unwilling to avoid using any tobacco products as required by the protocol during the study;\n24. Participation in any clinical trial within 3 months before screening (or within 12 months before screening for oligonucleotide drugs)\n25. In addition to the above requirements, female subjects who meet the following criteria should also be excluded: a. Pregnant or lactating women; b. Use of oral contraception within 28 days prior to screening; c. Use of long-acting estrogen and\u002For progesterone injections and\u002For implants within 6 months prior to screening; d. females of childbearing potential who had unprotected sexual intercourse with their partner within 28 days prior to dosing.\n26. Any other conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.","55 Years",{"count":157,"type":22},40,[159],"PHASE1","This is a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy subjects to evaluate the safety, tolerability, PK, and PD of SYH2061.",[26],"2026-06-04",{"date":164,"type":36},"2026-06-08",{"date":166,"type":36},"2025-12-23",{"date":168,"type":22},"2027-04-01",{"name":170,"class":171},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","INDUSTRY",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":52,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100641277","morpho-functional-evaluation-of-the-retina-and-choroid-using-multimodal-imaging-in-healthy-subjects-and-patients-with-retino-choroidal-diseases-100641277","NCT07615699","Morpho-functional Evaluation of the Retina and Choroid Using Multimodal Imaging in Healthy Subjects and Patients With Retino-choroidal Diseases","Valutazione Morfo-funzionale Della Retina e Della Coroide Mediante Imaging Multimodale in Soggetti Sani e in Pazienti Con Patologie Retino-coroideali","RET 05-26","Inclusion Criteria:\n\n* freely given informed consent acquired prior to the start of the study.\n* Participant's capacity to understand the informed consent and study procedures.\n* Age ≥ 6 years (with parental\u002Fguardian consent for minors).\n* Patients affected by any retino-choroidal disease.\n* Healthy subjects showing no retino-choroidal pathology.\n\nExclusion Criteria:\n\n* Patient unable and\u002For unwilling to cooperate.\n* Presence of media opacities (dioptric media) that prevent image acquisition or significantly reduce the quality of the obtained images.",{"count":181,"type":22},125,"The purpose of this prospective, longitudinal, single-center observational study is to identify, describe, and measure the morpho-functional characteristics and modifications of the retina and choroid using advanced multimodal imaging techniques. The study will evaluate patients affected by retino-choroidal diseases and compare them with healthy controls over a 5-year follow-up period to track the evolution of these parameters over time.",[184,185,26],"Retinal Diseases","Choroidal Diseases","2026-05-28",{"date":188,"type":36},"2026-05-29",{"date":40,"type":22},{"date":191,"type":22},"2033-06-01",{"name":193,"class":101},"Fondazione G.B. Bietti, IRCCS",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":52,"sex":17,"minAge":201,"maxAge":155,"enrollmentInfo":202,"targetDuration":4,"studyType":85,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":211,"locationsCount":44},"100629090","phase-1-bioequivalence-be-study-between-yhp2511-and-yhp2511a-in-healthy-volunteers-100629090","NCT07470125","Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of YHP2511 With YHP2511A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Adults aged 19 to 55 years at the time of screening visit.\n* Those whose weight is ≥ 50 kg (≥ 45 kg for females) and their body mass index (BMI) shall be between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases at the screening visit and without any pathological symptom or opinion after an internal medicine examination\n* Those who express their voluntary consent to participate in the trial by signing a written consent\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered with investigational products in 6 months prior to the first administration.\n* Others who are judged ineligible to participate in the trial by the principal investigator\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.","19 Years",{"count":84,"type":22},[159],"A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers",[26],{"date":207,"type":36},"2026-06-02",{"date":92,"type":22},{"date":210,"type":22},"2026-07-11",{"name":212,"class":171},"Yuhan Corporation",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":52,"sex":17,"minAge":201,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":85,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100637246","phase-1-bioequivalence-study-between-yhp2508c-and-yhr2603-in-healthy-subjects-100637246","NCT07584304","Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects","An Open-label, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508C and YHR2603 in Healthy Subjects","Inclusion Criteria:\n\n* BMI 18-30 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration.\n* Those who are judged ineligible to participate in the trial by the principal investigator.\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.","54 Years",{"count":222,"type":22},44,[159],"An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects",[26],[227,228],"Pharmacokinetics","Bioequivalence","2026-05-12",{"date":231,"type":36},"2026-05-13",{"date":233,"type":22},"2026-07-10",{"date":235,"type":22},"2026-09-15",{"name":212,"class":171},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":85,"phases":246,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":44},"100599186","early-phase-1-radiocaine-safety-study-100599186","NCT07081217","Radiocaine Safety Study","[18F]Radiocaine: Radiation and Radiochemical Safety","Inclusion Criteria:\n\n* 18 years and older\n* Able to provide written consent\n* Willing and able to undergo ECG, imaging, blood sampling, and complete self-assessment rating scales at the specified time points\n* Unremarkable baseline health without report of chronic or acute pain\n* Willing and able to participate in all imaging procedures and complete the self-assessment rating scales at the specified time points\n\nExclusion Criteria:\n\n* Body mass index (BMI) of 32 or greater, weight \\>300 lbs\n* Diagnosis of severe depression\u002Fanxiety (PROMIS score \\> 95%) or suicidal ideation\n* History of opioid abuse or opioid use disorder\n* History of seizures or epilepsy\n* History of major Axis I or Axis II psychiatric disorder that might, in the opinion of the investigator, make it difficult for the subject to complete all the procedures (e.g. obsessive-compulsive disorder, bipolar disorder, schizophrenia, or schizoaffective disorder)\n* History of cardiac arrhythmia\n* History of major orthopedic surgery within the last 12 months\n* Recent history (previous 6 months) of sodium channel blocker use, including, but not limited to: carbamazepine, lamotrigine, lidocaine, phenytoin, propranolol, or valproate\n* Any significant systemic illness or medical condition that could lead to difficulty complying with the study protocol\n* Creatinine clearance (calculated using the Cockcroft-Gault formula or measured) \\\u003C 60 mL\u002Fmin or serum creatinine \\>1.5 x ULN\n* QTcF \\>470 msec for females and QTcF \\>450 msec for males on screening ECG\n* MRI-incompatible implants, large tattoos, previous shrapnel injury\n* Pregnancy or lactating\n* History of contact sport participation, such as football, hockey, or rugby\n* Known claustrophobia related to MR or PET-MRI scanners\n* Recent blood donation\u002Fdraw of \\>1 unit (previous 4 weeks)\n* History of hypersensitivity to local anesthetics of the amide type\n* Family or personal history of familial malignant hyperthermia",{"count":245,"type":22},6,[247],"EARLY_PHASE1","This is a Phase 1, single-center, open-label study evaluating the safety, biodistribution, and radiation dosimetry of Radiocaine™, an investigational fluorine-18-labeled PET radiotracer designed to bind voltage-gated sodium channels. The study enrolls adult volunteers and aims to inform future clinical development in molecular imaging applications. Radiocaine™ is being developed as a potential diagnostic imaging agent and imaging biomarker for the localization and quantification of sodium channel activity.",[26],[251,252,253,254],"Radiocaine","PET imaging","medical imaging","diagnostic imaging","2026-05-06",{"date":257,"type":36},"2026-05-11",{"date":259,"type":36},"2025-06-17",{"date":96,"type":22},{"name":262,"class":171},"Lutroo Imaging LLC",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":270,"targetDuration":4,"studyType":85,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100600804","phase-1-a-study-to-evaluate-the-safety-tolerability-pkpd-of-hec-007-injection-in-healthy-and-overweightobese-subjects-100600804","NCT07102251","A Study to Evaluate the Safety, Tolerability, PK\u002FPD of HEC-007 Injection in Healthy and Overweight\u002FObese Subjects","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HEC-007 Injection After Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Overweight or Obese Subjects","Inclusion Criteria:\n\nSAD\n\n1. Subjects understand and comply with the study procedures, voluntarily participate, and sign the informed consent form.\n2. Healthy adult subjects (including borderline values) aged 18 to 45 years, regardless of sex.\n3. Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. BMI =Body weight (kg)\u002Fheight2 (m2), with a body mass index ranging from 19.0 to 35.0 kg\u002Fm2 (including boundary values).\n4. Normal results or abnormalities deemed clinically insignificant by the investigator in vital signs, physical examination, laboratory tests, electrocardiogram, chest CT, abdominal ultrasound (liver, gallbladder, spleen, pancreas, and both kidneys), and thyroid ultrasound.\n5. Female subjects of childbearing potential or male subjects must agree to use effective contraception from signing the informed consent until 6 months after the last administration of the investigational product to avoid pregnancy or impregnating a partner, with no plans for sperm or egg donation or pregnancy.\n6. Glycated hemoglobin (HbA1c) \\\u003C5.7% during the screening period. MAD\n\n1\\. Subjects understand and comply with the study procedures, voluntarily participate, and sign the informed consent form.\n\n2\\. Age between 18 to 65 years (inclusive), both male and female. 3. Obesity: BMI ≥28.0 kg\u002Fm2; or overweight: 24.0 \\\u003CBMI \\\u003C28.0 kg\u002Fm2, and with at least one of the following manifestations: prediabetes (as detailed in 14.4), hypertension, dyslipidemia, fatty liver, weight-bearing joint pain, obesity-related dyspnea, or obstructive sleep apnea syndrome.\n\n4\\. At screening, weight change of \\\u003C 5% over at least 12 weeks of diet and exercise control alone.\n\n5\\. Female subjects of childbearing potential or male subjects must agree to use effective contraceptionfrom signing the informed consent until 6 months after the last administration of the investigational product to avoid pregnancy or impregnating a partner, with no plans for sperm or egg donation or pregnancy.\n\n6\\. Glycated hemoglobin (HbA1c) \\\u003C6.5% during the screening period.\n\nExclusion Criteria:\n\nSAD\n\n1. Those diagnosed with type 1, type 2, or other types of diabetes before screening;\n2. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia syndrome type 2 (MEN2) during screening, or genetic predisposition to MTC;\n3. Acute, chronic, or suspected pancreatitis during screening, or prior pancreatectomy;\n4. Those diagnosed with any malignancy within 5 years before screening (except for basal cell carcinoma treated curatively and considered cured);\n5. Presence of clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disorders) during screening;\n6. Diseases or conditions affecting gastric emptying or gastrointestinal nutrient absorption during screening;\n7. Major surgery within 3 months before screening or planned surgery during the study;\n8. History of hypersensitivity to the investigational product or any of its components, or allergic constitution (allergy to two or more drugs or foods).\n9. Use of medications (including prescription drugs, over-the-counter drugs, herbal medicines, health supplements, etc.) within 3 months prior to screening that, in the investigator's judgment, significantly affect weight or glucose metabolism;\n10. Individuals who have undergone bariatric surgery prior to screening;\n11. Those with a history of recurrent skin disorders (e.g., urticaria) or skin lesions at the administration site;\n12. Those who received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled formulations) within 3 months prior to screening, or systemic glucocorticoid therapy within 1 month prior to screening;\n13. Female subjects with HbA1c \\\u003C110 g\u002FL or male subjects with HbA1c \\\u003C120 g\u002FL at screening, or any other known condition that interferes with HbA1c measurement;\n14. Those with suicidal behaviors or ideation within 6 months prior to screening;\n15. Use of GLP-1R, GLP-1R\u002FGIPR, GLP-1R\u002FGCGR, or GLP-1R\u002FGIPR\u002FGCGR agonists within 6 months prior to screening;\n16. Those with regular alcohol consumption within 3 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine); or those with a positive alcohol breath test during screening; or those unable to comply with the protocol's alcohol restrictions;\n17. Those with a history of drug abuse or illicit drug use within 2 years prior to screening, or those with a positive urine drug screen before administration;\n18. Smoking more than 5 cigarettes per day within 3 months prior to screening or inability to abstain from smoking during intensive PK blood sampling;\n19. Those with a history of needle or blood phobia, intolerance to venipuncture, or difficulty in blood collection;\n20. Those with positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum-specific antibody;\n21. Alanine aminotransferase \\>1.5 × upper limit of normal (ULN), aspartate aminotransferase \\>1.5 × ULN, alkaline phosphatase \\>1.5 × ULN, or total bilirubin \\>1.5 × ULN at screening;\n22. Those with blood amylase or lipase \\> ULN at screening;\n23. Those with serum calcitonin ≥20 ng\u002FL at screening;\n24. Those with fasting blood glucose ≥6.1 mmol\u002FL or \\\u003C3.9 mmol\u002FL at screening;\n25. Those with glomerular filtration rate (GFR) \\\u003C90 mL\u002Fmin\u002F1.73m2 at screening;\n26. Fridericia-corrected QT interval (QTcF=QT\u002FRR0.33) \\>450 ms (for male) or \\>470 ms (for female) on 12-lead ECG at screening;\n27. Use of strong inhibitors or inducers of hepatic metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4, and 3A5) within 4 weeks prior to the first dose, including strong inhibitors such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc., or strong inducers such as rifampin, carbamazepine, phenytoin sodium, St. John's wort, etc.;\n28. Use of any prescription drugs, over-the-counter medications, vitamin products, or Chinese herbal medicines within 2 weeks prior to the first dose;\n29. Consumption of any foods or beverages affecting CYP3A4, CYP2E1, or CYP2D6 metabolic enzymes, such as grapefruit or grapefruit-containing beverages, within 48 hours prior to the first dose;\n30. Ingestion of chocolate, any caffeine-containing or xanthine-rich food or beverage within 48 hours prior to the first dose;\n31. Blood donation ≥200 mL, any component blood donation, or total blood loss ≥200 mL due to any reason within 3 months prior to screening, or a history of blood transfusion or blood product use;\n32. Participation in other clinical trials within 3 months prior to screening (subjects who withdrew from the study before treatment, i.e., were not randomized or did not receive treatment, may be enrolled in this study);\n33. Occurrence of acute illness or concomitant medication use from the signing of the informed consent form until the first dose;\n34. Female subjects who are currently breastfeeding or have a positive pregnancy test result at screening;\n35. Subjects deemed by the investigator to have other factors unsuitable for participation in this trial.\n\nMAD\n\n1. Those diagnosed with type 1, type 2, or other types of diabetes before screening;\n2. Those diagnosed with overweight or obesity caused by other diseases or medications, such as Cushing's syndrome;\n3. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia syndrome type 2 (MEN2) during screening, or genetic predisposition to MTC;\n4. Acute, chronic, or suspected pancreatitis during screening, or prior pancreatectomy;\n5. Those diagnosed with any malignancy within 5 years before screening (except for basal cell carcinoma treated curatively and considered cured);\n6. Presence of clinically significant diseases at screening, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disorders (excluding weight-related comorbidities);\n7. Any of the following diseases or medical histories within 6 months prior to screening or before randomization: cardiac insufficiency (New York Heart Association \\[NYHA\\] Class III or IV), myocardial infarction, unstable angina, uncontrolled arrhythmias requiring treatment (including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, second- to third-degree atrioventricular block, sick sinus syndrome, etc.), coronary artery bypass grafting, percutaneous coronary intervention (diagnostic angiography allowed), cerebrovascular accident (ischemic stroke, hemorrhagic stroke, transient ischemic attack), cirrhosis, etc.;\n8. Diseases or conditions affecting gastric emptying or gastrointestinal nutrient absorption during screening;\n9. Major surgery within 3 months before screening or planned surgery during the study;\n10. History of hypersensitivity to the investigational product or any of its components, or to acetaminophen and its excipients, or allergic constitution (allergy to two or more drugs or foods);\n11. Use of medications (including prescription drugs, over-the-counter medications, Chinese herbal medicines, health supplements, etc.) within 3 months prior to screening that, in the investigator's judgment, significantly affect body weight;\n12. Subjects taking lipid-lowering or antihypertensive medications with unstable doses within 30 days prior to screening;\n13. Individuals who have undergone bariatric surgery prior to screening;\n14. Those with a history of recurrent skin disorders (e.g., urticaria) or skin lesions at the administration site;\n15. Those who received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled formulations) within 3 months prior to screening, or systemic glucocorticoid therapy within 1 month prior to screening;\n16. Female subjects with HbA1c \\\u003C110 g\u002FL or male subjects with HbA1c \\\u003C120 g\u002FL at screening, or any other known condition that interferes with HbA1c measurement;\n17. Those with suicidal behaviors or ideation within 6 months prior to screening;\n18. History of depression or other psychiatric disorders within 6 months prior to screening;\n19. Use of GLP-1R, GLP-1R\u002FGIPR, GLP-1R\u002FGCGR, or GLP-1R\u002FGIPR\u002FGCGR agonists within 6 months prior to screening;\n20. Those with regular alcohol consumption within 3 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine); or those with a positive alcohol breath test during screening; or those unable to comply with the protocol's alcohol restrictions;\n21. Those with a history of drug abuse or illicit drug use within 2 years prior to screening, or those with a positive urine drug screen before the first dose;\n22. Smoking more than 5 cigarettes per day within 3 months prior to screening or inability to abstain from smoking during intensive PK blood sampling;\n23. Those with a history of needle or blood phobia, intolerance to venipuncture, or difficulty in blood collection;\n24. Resting seated blood pressure at screening: systolic blood pressure \\>160 mmHg or \\\u003C90 mmHg, diastolic blood pressure \\>100 mmHg or \\\u003C55 mmHg;\n25. Heart rate at screening \\>100 beats per minute or \\\u003C50 beats per minute;\n26. Those with positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum-specific antibody;\n27. Alanine aminotransferase \\>2 × ULN, aspartate aminotransferase \\>2 × ULN, alkaline phosphatase \\>1.5 × ULN, or total bilirubin \\>1.5 × ULN at screening;\n28. Blood amylase or lipase \\> ULN at screening;\n29. Those with serum calcitonin ≥20 ng\u002FL at screening;\n30. Fasting triglyceride levels ≥5.6 mmol\u002FL at screening;\n31. Fasting blood glucose ≥7.0 mmol\u002FL or \\\u003C3.9 mmol\u002FL at screening; or OGTT 2-hour ≥11.1 mmol\u002FL;\n32. Those with glomerular filtration rate (GFR) \\\u003C90 mL\u002Fmin\u002F1.73m2 at screening;\n33. Fridericia-corrected QT interval (QTcF=QT\u002FRR0.33) \\>450 ms (for male) or \\>470 ms (for female) on 12-lead ECG at screening; or severe arrhythmia (second-degree or higher atrioventricular block, ventricular tachycardia, etc.);\n34. Use of strong inhibitors or inducers of hepatic metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4, and 3A5) within 4 weeks prior to the first dose, including strong inhibitors such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc., or strong inducers such as rifampin, carbamazepine, phenytoin sodium, St. John's wort, etc.;\n35. Consumption of any foods or beverages affecting CYP3A4, CYP2E1, or CYP2D6 metabolic enzymes, such as grapefruit or grapefruit-containing beverages, within 48 hours prior to the first dose;\n36. Ingestion of chocolate, any caffeine-containing or xanthine-rich food or beverage within 48 hours prior to the first dose;\n37. Blood donation ≥200 mL, any component blood donation, or total blood loss ≥200 mL due to any reason within 3 months prior to screening, or a history of blood transfusion or blood product use;\n38. Participation in other clinical trials within 3 months prior to screening (subjects who withdrew from the study before treatment, i.e., were not randomized or did not receive treatment, may be enrolled in this study);\n39. Occurrence of acute illness or concomitant medication use from the signing of the informed consent form until the first dose;\n40. Female subjects who are currently breastfeeding or have a positive pregnancy test result at screening;\n41. Subjects deemed by the investigator to have other factors unsuitable for participation in this trial.",{"count":271,"type":22},126,[159],"This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects.\n\nThe trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, planning to enroll 72 Chinese overweight or obese subjects.",[26],"2026-04-24",{"date":277,"type":36},"2026-04-27",{"date":279,"type":36},"2025-09-21",{"date":281,"type":22},"2026-12-31",{"name":283,"class":171},"Sunshine Lake Pharma Co., Ltd.",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":52,"sex":291,"minAge":18,"maxAge":155,"enrollmentInfo":292,"targetDuration":4,"studyType":85,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":4},"100636003","phase-1-a-comparative-pharmacokinetic-study-of-cm326-in-healthy-subjects-100636003","NCT07560033","A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects","A Randomized, Open-Label, Parallel-Controlled Phase I Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of a Single Subcutaneous Injection of CM326 Via Different Delivery Devices in Healthy Subjects","Inclusion Criteria:\n\n1. Participants \\[c1.1\\]must be informed of the study before it begins, fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;\n2. Healthy male participants aged 18 to 55 years;\n3. Body weight between 55.0 and 85.0 kg, and body mass index between 19.0 and 26.0 kg\u002Fm²;\n4. Physical examination, vital signs, 12-lead electrocardiogram, laboratory tests, and other examination results are normal, or abnormal but without clinical significance;\n5. Participants and their partners agree to use effective and reliable contraceptive methods from signing the ICF until 3 months after dosing;\n6. Participants are able to communicate well with the investigator, and to understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. History of chronic diseases or severe diseases involving the circulatory system, blood or hematopoietic system, respiratory system, endocrine system, urinary system, digestive system, immune system, psychiatric or nervous system, reproductive system, etc.;\n2. Presence or suspicion of any active viral, bacterial, fungal, or parasitic infection within 14 days before dosing;\n3. Participants who have undergone major surgery within 3 months before screening, or who plan to undergo major surgery during the study period;\n4. History of allergies to drugs, food, etc., or Participants who may be allergic to the study drug or its components in the Investigator's judgment;\n5. Positive result for any of the following: hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody, human immunodeficiency virus antigen\u002Fantibody;\n6. History of drug abuse, or use of illicit drugs within 3 months before screening, or habitual use of any psychotropic drugs (including herbal medicines), or a positive urine drug screen;\n7. Blood loss or blood donation of more than 200 mL within 3 months before screening;\n8. Intolerance to subcutaneous injection, or presence of abdominal scars that affect subcutaneous administration, and any skin abnormalities and\u002For tattoos that may affect the safety assessment of the injection site;\n9. Use of any prescription drugs, over-the-counter drugs, herbal medicines or vitamin and dietary supplements within 14 days or 5 half-lives (whichever is longer) before dosing;\n10. Use of any marketed or investigational biological products within 6 months or 5 half-lives (whichever is longer) before dosing;\n11. Participants who have previously used CM326 or drugs targeting TSLP;\n12. Vaccination within 4 weeks before screening, or plan to receive such vaccines during the study;\n13. Participation in any clinical trial within 3 months before screening;\n14. Average daily smoking of more than 5 cigarettes within 3 months before screening, or unwilling to avoid using any tobacco products during the study;\n15. Regular alcohol consumption within 3 months before screening, defined as weekly alcohol consumption exceeding 14 units (1 unit = 360 mL of 5% alcohol beer or 45 mL of 40% alcohol spirits or 150 mL of 12% alcohol wine), or inability to stop alcohol intake during the study, or a positive blood alcohol test;\n16. Regular consumption of excessive amounts of tea, coffee, and\u002For caffeinated beverages within 3 months before screening;\n17. Participants who have special dietary requirements and are unable to comply with the standardized diet;\n18. History of needle phobia or hemophobia, or d difficulty with venipuncture or unable to tolerate venous puncture;\n19. Participants who, in the Investigator's judgment, may be unable to complete the study for other reasons or are considered unsuitable for enrollment.","MALE",{"count":293,"type":22},192,[159],"This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.",[26],"2026-04-23",{"date":299,"type":36},"2026-04-30",{"date":301,"type":22},"2026-04-20",{"date":281,"type":22},{"name":304,"class":171},"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":85,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":147},"100419829","functional-near-infrared-spectroscopy-in-unconscious-patients-100419829","NCT04746820","Functional Near-infrared Spectroscopy in Unconscious Patients","Prognostic Value of Functional Near-infrared Spectroscopy in Unconscious Neurocritical Care Patients- a Prospective Pilot Study","fNIRS","Inclusion Criteria - experimental group:\n\n* Patients of either sex with severe hemorrhagic, ischemic stroke or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation treated at the Institute of Intensive Care Medicine, University Hospital Zurich\n* Unconsciousness (GCS \\\u003C 9) or sedated to the severity of the disease (for the subgroup of patients included in the fNIRS-EEG measurement unconscious patients are defined as not responding to verbal stimuli. The motor response to pain should be one of the following: no response to pain \u002F extensor response \u002F flexor response \u002F localize to pain)\n* Age ≥ 18 years\n* Signed informed consent obtained from legal representative\n* Measurement logistically and technical possible within the first 7 days after admission\n\nInclusion Criteria - control group:\n\n* Subjects of either sex\n* Conscious (GCS = 15)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria - experimental group:\n\n* Patients age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease\n* Concomitant instable critical illness (e.g. sepsis, multi-organ failure, hemodynamic or respiratory instability)\n* Acute status epilepticus\n* Clinical recovery (GCS ≥ 9) or death before enrolment of the study\n\nExclusion Criteria - control group:\n\n* Subjects age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease",{"count":314,"type":22},30,[87],"The study design is a single-center prospective pilot study. Hypothesis: Results of cerebral fNIRS examination in unconscious patients with severe hemorrhagic or ischemic stroke in the ICU are congruent with the results of SSEP and AEP. Hence, making it a potential prognostic tool for unconscious ICU patients.\n\nIn a specific subgroup of unconscious patients after cardiac arrest and cardiopulmonary resuscitation the fNIRS measurement is congruent with the results of electroencephalography (EEG).\n\nThe primary purpose of this study is to evaluate the agreement of the results of fNIRS examination to those of evoked potentials and EEG in unconscious ICU patients with severe hemorrhagic, or ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation.\n\nfNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.\n\nTo compare fNIRS with evoked potentials there are two test phases:\n\n1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP\n2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP\n\nTo avoid biases the following has to be considered:\n\n* The timing of the measurements plays an important role. A time difference between compared measurements can influence the outcome significantly due to deterioration or recovery of the neuronal network during the time gap. Therefore, fNIRS and evoked potentials will be measured simultaneously.\n* If the compared measurement methods are conducted by the same researcher the possibility of bias is high. Hence, two different researcher will conduct each one measurement without knowing the results of each other during the measurement.",[318,26],"Nervous System Diseases",[320,321,322,323,324,325],"severe cerebral hemorrhage","ischemic stroke","unconscious neurocritical care patients","functional near-infrared spectroscopy","evoked potentials","electroencephalography","2026-04-21",{"date":277,"type":36},{"date":329,"type":36},"2020-01-15",{"date":281,"type":22},{"name":332,"class":101},"Emanuela Keller",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":85,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":44},"100631773","phase-1-first-in-human-study-of-ish0688-safety-tolerability-pharmacokinetics-and-pharmacodynamics-100631773","NCT07505043","First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate ISH0688 Subcutaneous Injection","Inclusion Criteria:\n\n1. Female subjects:\n\n   * Not of childbearing potential: Including surgical sterilization performed at least 6 weeks prior to screening (with documented records of bilateral tubal ligation, bilateral salpingectomy, hysterectomy, or bilateral oophorectomy), or postmenopausal with continuous amenorrhea for ≥12 months; or\n   * Of childbearing potential: Must not be pregnant or breastfeeding, and must agree to use adequate contraception from 30 days prior to first dosing throughout the study period and for 6 months after the last dose;\n   * Serum β-human chorionic gonadotropin (β-hCG) pregnancy test results must be negative at both screening and baseline visits;\n2. Male subjects with female partners of childbearing potential must agree to use adequate contraception from 30 days prior to first dosing throughout the study period and for 6 months after the last dose;\n3. Male subjects must have no plan to donate sperm from the time of informed consent signing until 6 months after study completion; female subjects must have no plan to donate eggs from the time of informed consent signing until 6 months after study completion;\n4. All subjects must be able to understand the procedures and methods of this study, be willing to strictly comply with the clinical study protocol to complete this study, and voluntarily sign the informed consent form.\n\nAdditional inclusion criteria for Part 1:\n\n1. Male or female subjects aged 18 to 65 years (inclusive);\n2. Male body weight ≥50.0 kg, female body weight ≥45.0 kg, with body mass index (BMI) ≥19.0 and \\\u003C28.0 kg\u002Fm²;\n3. Fasting triglycerides (TG) \\\u003C2.3 mmol\u002FL (200 mg\u002FdL);\n4. Comprehensive vital signs, physical examination, 12-lead electrocardiogram (ECG), chest X-ray, abdominal ultrasound, and laboratory tests (complete blood count, blood biochemistry, urinalysis, stool routine, coagulation function, thyroid function) showing no abnormalities or only minor abnormalities that are judged by the investigator to be of no clinical significance. For clinically significant abnormal laboratory findings, retesting may be performed within one week if there is a clear and reasonable justification, and the retest results will be used to determine subject eligibility.\n\nAdditional screening period inclusion criteria for Part 2:\n\n1. Male or female subjects aged 18 to 75 years (inclusive);\n2. Male body weight ≥50.0 kg, female body weight ≥45.0 kg, with body mass index (BMI) in the range of 19.0 to 45.0 kg\u002Fm² (inclusive);\n3. Lipid levels at screening or within 1 week prior to screening (at this site) meeting: fasting TG ≥2.3 mmol\u002FL (200 mg\u002FdL);\n4. Lipid-lowering medication use within 28 days prior to screening must meet the following criteria: For TG \\\u003C5.7 mmol\u002FL (500 mg\u002FdL): no lipid-lowering medication use or receiving stable-dose lipid-lowering therapy for ≥28 days; For TG ≥5.7 mmol\u002FL (500 mg\u002FdL): must first receive stable-dose lipid-lowering therapy for ≥28 days; (Lipid-lowering therapy: niacin, prescription-grade fish oil, fibrates, statins, cholesterol absorption inhibitors, etc.; PCSK9 inhibitors require 6 months of stability prior to screening);\n5. At screening, liver fat content (LFC) assessed by MRI-PDFF ≥8% in some participants;\n6. Able to accept therapeutic lifestyle interventions consistent with local standards and maintain stable lifestyle throughout the study period, avoiding alcohol consumption and strenuous exercise within 48 hours prior to each visit.\n\nAdditional double-blind treatment period inclusion criteria for Part 2:\n\n1. Meet all inclusion criteria and do not meet any exclusion criteria during the screening period;\n2. Undergo therapeutic lifestyle intervention during the lead-in period, maintain a stable lifestyle, and be judged by the investigator as capable of complying with the protocol to receive study treatment and complete other clinical trial procedures;\n3. Two TG tests during the lead-in period with an interval of ≥7 days, with the mean of the 2 TG values meeting 2.3 mmol\u002FL (200 mg\u002FdL) ≤ fasting TG \\\u003C 11.3 mmol\u002FL (1000 mg\u002FdL);\n4. The last TG test is within 7 days prior to the first dosing (D1).\n\nExclusion Criteria:\n\n1. Subjects with current allergic diseases, history of allergy to therapeutic or diagnostic protein products, or allergy to two or more drugs and\u002For non-drug factors;\n2. Subjects with history of malignant tumors (regardless of cure status, except for basal cell carcinoma, squamous cell skin cancer, and cervical carcinoma in situ);\n3. Subjects with positive results for one or more of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or serum treponema pallidum antibody (TP-Ab) (if HBsAg positive, must also have positive HBV-DNA; if HCV-Ab positive, must also have positive HCV-RNA);\n4. Subjects with severe trauma or surgical history within 6 months prior to screening; or subjects planning to undergo surgery (including cosmetic surgery, dental surgery, and oral surgery, etc.) during the trial period;\n5. Subjects with body weight change ≥5% within 3 months prior to screening (self-reported), or use of other medications\u002Ftreatments for weight reduction within 1 month prior to screening or planned during the study period;\n6. Subjects with history of frequent orthostatic hypotension episodes within 6 months prior to screening;\n7. Subjects with history of chronic pancreatitis or acute pancreatitis attack within 1 year prior to screening;\n8. Subjects with gallbladder history and symptoms (such as: common bile duct stones, multiple gallbladder stones, etc., unless cholecystectomy performed and ≥6 months since surgery);\n9. Subjects with alcohol consumption \\>14 units per week within 3 months prior to screening (1 unit of alcohol = 360 mL beer, 150 mL wine, or 45 mL spirits with 40% alcohol content), or positive alcohol breath test (at baseline);\n10. Drug abusers or subjects using soft drugs (e.g., marijuana) within 3 months prior to screening or hard drugs (e.g., cocaine, phencyclidine, etc.) within 1 year prior to screening, or positive drug abuse screening (morphine, ketamine, tetrahydrocannabinol acid, methamphetamine, methylenedioxymethamphetamine, cocaine);\n11. Subjects who have used products targeting FGF21 within 1 year prior to screening, such as BIO89-100, DR10624, etc.;\n12. Subjects with history of vaccination within 3 months prior to screening, or planning to receive vaccination during the trial period;\n13. Subjects who participated in any other clinical trial of drugs or medical devices within 3 months prior to screening (except those who did not use investigational drugs\u002Fmedical devices); or subjects within 5 half-lives of a drug (if 5 half-lives of the investigational drug exceed 3 months);\n14. Subjects who donated blood or experienced massive blood loss (\\>400 mL, excluding female menstrual period) or received blood transfusion or blood products within 3 months prior to screening, or subjects planning to donate blood during the trial period;\n15. Subjects with severe infection within 3 months prior to screening, including but not limited to: severe pneumonia, lung abscess, meningitis, cellulitis, etc., judged by the investigator as unsuitable for participation in this trial;\n16. Subjects with strenuous exercise during the trial period, or significant changes in exercise or dietary habits;\n17. History of needle phobia or blood phobia, or inability to tolerate venipuncture;\n18. Subjects with dermatitis or abnormal skin conditions at or around the administration site;\n19. Subjects whom the investigator considers unsuitable for participation in this study for any other reason.\n\nAdditional exclusion criteria in Part 1:\n\n1. Abnormal vital signs at screening in one or more parameters, or abnormal 12-lead electrocardiogram, or clinically significant abnormal physical examination findings;\n2. Clinically significant abnormal laboratory findings meeting the following criteria: alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin (TBIL) \\>1.5×ULN; estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin\u002F1.73m²;\n3. Presence of severe, progressive, or uncontrolled diseases, including but not limited to immune system, endocrine system, hematological system, urinary system, hepatobiliary system, respiratory system, nervous system, psychiatric system, cardiovascular system, or digestive system disorders, which in the judgment of the investigator would increase the risk to the subject by participating in this study;\n4. Use of any prescription drugs, over-the-counter drugs, proprietary Chinese medicines, or herbal medicines within 14 days or 5 half-lives prior to screening (whichever is longer) (excluding oral contraceptives, acetaminophen, and ibuprofen);\n5. Smoking more than 5 cigarettes per day on average within 3 months prior to screening;\n6. Excessive consumption of tea, coffee, or caffeine-containing beverages within 3 months prior to screening (more than 8 cups per day of corresponding beverages, 1 cup = 250 mL), or consumption of any caffeine-containing food or beverages (such as coffee, strong tea, chocolate, cola, etc.) within 48 hours prior to first dosing.\n\nAdditional exclusion criteria in Part 2:\n\n1. Known diagnosis of familial chylomicronemia syndrome (FCS) (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III); or strong suspicion of any of the above 3 conditions;\n2. Body weight decrease ≥5% from screening period to prior to receiving double-blind treatment;\n3. Clinically significant 12-lead electrocardiogram (ECG) abnormalities at screening;\n4. Clinically significant abnormal laboratory findings meeting the following criteria: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>3.0×ULN, total bilirubin (TBIL) \\>2.0×ULN, creatine kinase (CK) \\>1.5×ULN; creatinine (Cr) \\>176 μmol\u002FL and\u002For estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²; hemoglobin \\\u003C110 g\u002FL (males) or \\\u003C100 g\u002FL (females); platelet count (PLT) \\\u003C60×10⁹\u002FL; thyroid stimulating hormone (TSH) \\\u003Clower limit of normal (LLN) or \\>1.5×ULN; serum amylase or lipase \\>2.0×ULN;\n5. Type 1 diabetes mellitus; or newly diagnosed Type 2 diabetes mellitus within 3 months; or poorly controlled Type 2 diabetes mellitus (HbA1c ≥9.5%); or Type 2 diabetes mellitus with severe complications; or failure to maintain stable dose of hypoglycemic agents for ≥3 months prior to screening;\n6. Uncontrolled or poorly controlled hypertension at screening: resting seated systolic blood pressure (SBP) ≥160 mmHg and\u002For diastolic blood pressure (DBP) ≥100 mmHg; or failure to maintain stable dose of antihypertensive agents for ≥3 months prior to screening;\n7. Use (≥3 days) of other drugs significantly affecting blood lipids from 28 days prior to screening through the entire trial period (excluding lipid-lowering drugs specified in Inclusion Criterion 4), including proprietary Chinese medicines containing statin components, and other drugs and health supplements with lipid-lowering effects;\n8. Presence of other severe, progressive, or uncontrolled diseases in addition to T2DM, hypertension, and dyslipidemia, including but not limited to immune system, endocrine system, hematological system, urinary system, hepatobiliary system, respiratory system, nervous system, psychiatric system, cardiovascular system, or digestive system disorders, which in the judgment of the investigator would increase the risk to the subject by participating in this study;\n9. Subjects who, in the investigator's assessment, require systemic corticosteroid therapy during the study period due to comorbidities, or who have received continuous or cumulative systemic corticosteroid therapy for more than 14 days within 6 months prior to screening (stable-dose inhaled or topical corticosteroids are permitted);\n10. Presence of contraindications to MRI examination or inability to cooperate with MRI examination;\n11. New York Heart Association (NYHA) Class III or IV congestive heart failure;\n12. Atherosclerotic cardiovascular disease within 6 months prior to screening;\n13. Major cardiovascular or cerebrovascular events within 6 months prior to screening;\n14. Severe arrhythmia within 3 months prior to screening;\n15. History of or current nephrotic syndrome, severe liver disease, Cushing's syndrome, or other diseases significantly affecting blood lipid levels;\n16. History of or current hyperthyroidism or hypothyroidism.","75 Years",{"count":342,"type":22},104,[159],"ISH0688 is a human IgG1 Fc-FGF21 fusion protein. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of ISH0688 via subcutaneous injection.",[26,346],"Hyperlipidemia, Hypertriglyceridemia","2026-03-26",{"date":349,"type":36},"2026-04-01",{"date":351,"type":22},"2026-03-01",{"date":353,"type":22},"2027-02-28",{"name":355,"class":171},"SUNHO（China）BioPharmaceutical CO., Ltd.",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":85,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":44},"100517205","early-phase-1-single-tracer-multiparametric-pet-imaging-100517205","NCT06014515","Single-tracer Multiparametric PET Imaging","Inclusion Criteria:\n\n1. Inclusion Criteria for all research participants:\n\n   * Adults (age ≥ 18 years old)\n   * Ability to understand and willingness to sign an informed consent form\n   * Ability to adhere to the study visit schedule and other protocol requirements.\n   * Willing and able to fast for at least 6 hours before and for the duration of the scan\n   * No strenuous exercise for 24 hours prior to being scanned\n   * Willing to lie on the scanner bed for up to 60 minutes\n   * Free of active COVID-19 symptoms\n2. Inclusion Criteria for healthy volunteers only:\n\n   • Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in normal tissue perfusion and\u002For metabolism.\n3. Inclusion Criteria for patients with disease:\n\n   * Patients with clinically acute or chronic conditions such as cardiovascular, cardiometabolic, or cardiopulmonary diseases, which may include but are not limited to ischemic heart disease, myocarditis, arrhythmias, heart failure, nonalcoholic fatty liver disease, COVID-related sequala, diabetes, hypertension, or renal disease that would result in changes in normal tissue perfusion and\u002For metabolism.\n\nExclusion Criteria:\n\nParticipants are not eligible if they meet ANY of the following criteria:\n\n* Self-reported history of dysphoria or anxiety in closed spaces\n* Body weight \\>240 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available)\n* Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Prisoners\n* Any condition that would prevent the understanding or rendering of informed consent.\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.",{"count":84,"type":22},[247],"The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.",[26,366],"Cardiovascular Disease",[368],"total body positron emission tomography","2026-03-09",{"date":371,"type":36},"2026-03-10",{"date":373,"type":36},"2024-02-14",{"date":375,"type":22},"2033-08",{"name":377,"class":101},"University of California, Davis",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":85,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":44},"100412059","optimization-of-the-acquisition-sequence-to-improve-the-quality-and-comfort-of-magnetic-resonance-imaging-exam-100412059","NCT04645628","Optimization of the Acquisition Sequence to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam","AIMANT","Inclusion Criteria for all subjects :\n\n* to be over 18 year-old,\n* to be able to understand the instructions given,\n* to be enrolled in a social security plan,\n* to have underwent a pre-inclusion medical examination,\n* to give a written consent.\n\nInclusion Criteria especially for Patients :\n\n* to perform a MRI examination of the head, neck, spine, thorax, abdomen, pelvis, retroperitoneum, lower limbs, upper limbs or whole body during clinical follow-up care.\n\nExclusion Criteria for all subjects :\n\n* any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ),\n* subject under a measure of legal protection.\n\nExclusion Criteria especially for Healthy Subjects :\n\n* to have a pathology in the anatomical area to be imaged\n* to be employed by the CHRU of Nancy or having the slightest link of subordination with the CHRU of Nancy.\n\nExclusion Criteria especially for Patients :\n\n* to have a limited MRI examination time due to a sensitive clinical situation (sedation, unstable hemodynamic state, postoperative).",{"count":386,"type":22},720,[87],"The purpose of this study is to evaluate the optimization of MRI acquisition sequences.",[26,390],"Patient Performing an MRI Examination","2026-03-02",{"date":393,"type":36},"2026-03-04",{"date":395,"type":36},"2020-12-04",{"date":397,"type":22},"2028-12-01",{"name":146,"class":101},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":52,"sex":17,"minAge":406,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100609043","shoulder-strength-in-baseball-players-100609043","NCT07209423","Shoulder Strength in Baseball Players","Shoulder Strength in Light of Retroversion and Biological Age in Baseball Players","Inclusion Criteria:\n\n* Able to participate in baseball activities\n* All races and ethnicities.\n* Speaks and understands English or Japanese.\n\nExclusion Criteria:\n\nA diagnosis of a current injury that prevents participation in baseball activities.\n\n* Orthopedic conditions (e.g., muscle strain, ligament sprain)\n* Vascular history (e.g., blood clots, vascular surgery, varicose veins)\n* Neurological history (e.g., stroke, nerve injury, or cognitive impairment)\n* Cardiopulmonary conditions (e.g., hypertension, heart disease)\n* Any history of bleeding or clotting disorders\n* Diabetes, cancer, rhabdomyolysis, or compartment syndrome\n* Additionally, not maintaining participant's regular diet on the day of the research will also impact eligibility.","15 Years","22 Years",{"count":134,"type":22},"The purpose of this graduate student research study is to transform the existing concepts surrounding shoulder strength in baseball players, particularly in the context of retroverted shoulders.",[26],[412,413],"baseball","shoulder","2026-02-02",{"date":416,"type":36},"2026-02-04",{"date":418,"type":22},"2026-04",{"date":420,"type":22},"2026-11-20",{"name":422,"class":101},"Loma Linda University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":431,"targetDuration":4,"studyType":85,"phases":433,"briefSummary":434,"conditions":435,"keywords":439,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":147},"100606885","phase-1-a-phase-1-study-of-gtx-b001-in-healthy-subjects-and-patients-with-chronic-inducible-urticaria-100606885","NCT07181369","A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients With Chronic Inducible Urticaria (Part B)","CHILL-MC","Key inclusion Criteria (Part A):\n\n* The subject is between 18 and 55 years of age (both inclusive) at the date of screening.\n* The subject is in good general health based on the medical history, physical examination and the results of vital signs, electrocardiogram and clinical laboratory, as judged by the investigator.\n\nKey inclusion Criteria (Part B):\n\n* The subject is between 18 and 75 years of age (both inclusive) at the date of screening\n* A history of signs and\u002For symptoms of ColdU or SD experienced ≥ 3 months prior to screening.\n* For ColdU patients, a positive provocation test during screening and baseline, using the TempTest® device.\n* For SD patients, a positive provocation test with at least 3 pins during screening and baseline, using the FricTest® device.\n* Inadequate control of ColdU or SD by second generation H1-antihistamine (sgAH) as defined as the presence of itch and hives following a trigger (e.g. cold or scratching, respectively) within the last 6 weeks prior to screening in spite of use of a sgAH.\n* A Urticaria Control Test (UCT) score of \\\u003C 12 at screening.\n\nKey exclusion Criteria (Parts A \\& B):\n\n* Presence of any clinically significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder that would interfere with the patient's safety or the interpretation of trial results in the judgment of the investigator.\n* Treatment with an investigational drug or intervention for any condition within three months of screening, or concurrent participation in another clinical trial in which an investigational drug is administered.\n* Treatment with immunomodulating therapy (e.g., intravenous or intramuscular immunoglobulins, systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus, mycophenolate mofetil, hydroxychloroquine, infliximab, adalimumab, etanercept, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.\n* Use of any monoclonal antibody or therapeutic protein within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.\n* History of anaphylaxis, autoimmune disorders requiring more than topical medication, or asthma requiring regular use of inhaled medication within the past 5 years, unless, in the opinion of the Investigator, the condition is not considered clinically significant and is unlikely to affect subject safety or study outcomes.\n\nAdditionally for Part B:\n\n* Disease with symptoms of urticaria or angioedema other than Chronic Urticaria (CU), for example urticaria vasculitis, erythema multiforme, mastocytosis, or drug-induced urticaria. Patients with concomitant Chronic Spontaneous Urticaria (CSU) or other forms of Chronic Inducible Urticaria (CIndU) are eligible provided that symptoms at screening are consistent with ColdU or SD and that ColdU or SD is the dominant form of CU.\n* Any other skin disease associated with chronic itching that might influence in the investigators' opinion of the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or psoriasis.\n* Receipt of any biologic therapy for urticaria control (e.g. omalizumab, dupilumab, ligelizumab, etc.) within three months of screening (whether on-label or off-label).",{"count":432,"type":22},72,[159],"This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.",[26,436,437,438],"Cold Urticaria","Symptomatic Dermographism","Chronic Inducible Urticaria",[440,441,442,443,444,445,446,447,448,227,449,450,451,452],"Urticaria","Skin diseases","Mast cells","Bispecific antibody","GTX-B001","Infusion","Single Ascending Dose","Healthy subjects","Safety","Pharmacodynamics","Cold urticaria","Intravenous","symptomatic dermographism","2026-01-28",{"date":455,"type":36},"2026-01-30",{"date":457,"type":36},"2025-10-06",{"date":459,"type":22},"2027-08",{"name":461,"class":171},"Granular Therapeutics Limited",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":85,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":44},"100609850","phase-1-a-study-to-investigate-hla-g-targeted-exosome-sob100-in-healthy-subjects-100609850","NCT07219940","A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects","An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects","αHLA-G Exo-01","Inclusion Criteria:\n\n1. Male or female subjects aged ≥ 18 years old\n2. Overtly healthy subject, who is considered to be generally healthy based on medical history, 12-lead ECG, and physical examinations, as judged by the Investigator\n3. Able to understand and comply with procedures in the protocol as judged by Investigator and sign the informed consent form (ICF)\n4. Adequate organ function\n\nExclusion Criteria:\n\n1. With known or suspected to be hypersensitivity to HLA-G related treatment.\n2. Confirmed active HIV, HBV, or HCV infection\n3. With active fungal, bacterial, viral or atypical infection requiring systemic medication\n4. History of cancer (malignancy) or have ever received any anti-cancer therapy\n5. Has ever received cell therapy or organ transplantation\n6. Substance abuse or addictive use of drugs for nonmedical purposes\n7. Female subject is lactating, has a positive pregnancy test or refuse to practice highly effective contraception\n8. Male subjects with a female spouse\u002Fpartner who is of childbearing potential refuse to adopt at least one highly effective method of contraception",{"count":471,"type":22},15,[159],"The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.",[26,475,476],"Exosome","Targeted Therapy","2026-01-22",{"date":479,"type":36},"2026-01-26",{"date":481,"type":36},"2025-12-01",{"date":483,"type":22},"2027-03",{"name":485,"class":171},"Shine-On Biomedical Co., Ltd.",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":493,"targetDuration":4,"studyType":85,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":44},"100527275","intramuscular-temperature-on-the-echo-textural-characteristics-100527275","NCT06145646","Intramuscular Temperature on the Echo-textural Characteristics","Influence of Intramuscular Temperature on the Textural Characteristics of the B-mode Ultrasound Image.","Inclusion Criteria:\n\n* Acceptance of participation in the study.\n* Healthy subjects.\n* Subjects between the ages of 18 and 65.\n\nExclusion Criteria:\n\n* Have known neurological, cardiovascular, metabolic or orthopedic conditions that prevent them from participating in the study.\n* Present metal implants in the heating area.\n* Wear a pacemaker.\n* Perform physical activity during the 48 hours prior to data collection.\n* Contraindications of dry needling such as: Belonephobia, history of abnormal reaction to the puncture or injection, anticoagulant treatment or thrombocytopenia, lymphedema over the area of intervention, severely compromised immune system, vascular diseases, diabetes mellitus, pregnancy, epilepsy, allergy to metals or that the intervention area has wounds, scars, tattoos, or stains.",{"count":314,"type":22},[87],"Echointensity and echotexture have been used as a physiological marker for changes in skeletal muscle quality and structure caused by physical training, low activity, ageing and some neuromuscular disorders. However, there are some influencing factors on muscle echo-intensity and echotexture, such as temperature, which may not be taken into account when performing an ultrasound assessment and may alter the results.\n\nThis study aims to investigate the effects of muscle temperature on echointensity and other 2nd order echotextures variables such as homogeneity, contrast, correlation and entropy of muscle tissue, in order to gain a better understanding of this correlation and minimise its influence, which would allow greater precision in the use of muscle ultrasound as a diagnostic tool.\n\nThe methodology of this study includes firstly the acquisition of ultrasound images of the vastus lateralis muscle. This acquisition will be performed during the continuous recording of muscle temperature, carried out during a passive cooling process after 20 min of heating using microwave equipment. In addition, to standardise the results, a correction factor will be calculated to compensate for the influence of subcutaneous adipose tissue thickness on echogenicity and echotexture.",[26],[498,499,500,501,502],"muscle","temperature","texture","ultrasound","echo intensity","2026-01-20",{"date":477,"type":36},{"date":506,"type":36},"2023-11-30",{"date":301,"type":22},{"name":509,"class":101},"Cardenal Herrera University",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":517,"enrollmentInfo":518,"targetDuration":519,"studyType":23,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":44},"100619900","noninvasive-real-time-arterial-waveform-monitoring-for-cardiovascular-disease-assessment-100619900","NCT07350629","Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment","A Study on Noninvasive Real-Time Arterial Pressure Waveform Analysis for the Detection and Evaluation of Cardiovascular Diseases","Inclusion Criteria:\n\n* Age 18-80 years\n* Able to provide informed consent\n* For AR group: clinically diagnosed aortic regurgitation\n* For AS group: clinically diagnosed aortic stenosis\n* For healthy controls: no history of cardiovascular disease\n* Able to undergo finger arterial waveform measurement\n\nExclusion Criteria:\n\n* History of recent cardiac surgery or intervention (\\\u003C6 months)\n* Hand disorders affecting finger mobility (e.g., arthritis)\n* Pregnant or breastfeeding women\n* Participation in other studies affecting arterial waveform\n* Unable to understand or comply with study procedures","80 Years",{"count":471,"type":22},"1 Day","The goal of this observational study is to learn whether noninvasive real-time arterial waveform monitoring can be used to assess cardiovascular diseases in adults. The main question it aims to answer is:\n\nCan photoacoustic imaging accurately capture arterial waveforms from patients' fingers? Can features extracted from the arterial waveforms reflect the type and severity of cardiovascular diseases? Participants will be asked to place their fingers into the imaging device, where their finger arterial pulse information will be noninvasively recorded.",[522,523,26],"Aortic Regurgitation Disease","Aortic Stenosis Disease","2026-01-11",{"date":503,"type":36},{"date":527,"type":36},"2025-12-26",{"date":529,"type":22},"2026-02",{"name":531,"class":101},"Anhui Provincial Cancer Hospital",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":85,"phases":542,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":44},"100618420","phase-1-a-drug-drug-interaction-study-of-hdm1002-and-metformin-empagliflozin-midazolam-valsartan-and-warfarin-100618420","NCT07331389","A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight\u002FObese Adult Chinese Subjects","Inclusion Criteria:\n\n1. According to the medical history, clinical laboratory test results, vital sign measurements, 12 lead ECG results, and physical examination results during the screening period, the investigator considers the subject to be in good general health.\n2. Age range of 18-45 years old (including range), no limit to gender.\n3. Subject weighed ≥50.0 kg, and a body mass index (BMI) within the range of 24.0 - 35.0 kg\u002Fm2 (including cut-off values).\n\nExclusion Criteria:\n\n1. Subject has a history or family history of medullary thyroid cancer, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2), or calcitonin≥50 ng\u002FL during the screening period.\n2. History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening.\n3. History of acute cholecystitis attack within 3 months prior to screening.\n4. Severe hypoglycemic events or recurrent hypoglycemic events occurred within 3 months prior to screening\n5. Subject judged by investigator has dysphagia, diseases or conditions that affect gastric emptying, or affect the absorption of gastrointestinal nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, etc.\n6. Any pre-existing conditions that increase the risk of bleeding, such as acute gastritis or active ulcers with bleeding, hemorrhagic cerebral infarction, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, and active pathological bleeding, etc\n7. History of previous surgery that will affect the absorption, distribution, metabolism, and excretion of drugs or plan to undergo surgery during the study period.\n8. During screening period, any abnormalities in physical examination, electrocardiogram, laboratory tests, and vital signs which are of clinically significant .\n9. Taken or planned to take any drug that effect liver enzyme or transporter activity within 28 days prior to taking the investigational drug.\n10. History of clinically significant cardiovascular and cerebrovascular disease within 6 months prior to screening or at the time of admission.\n11. Presence of clinically significant ECG results judged by the investigator at screening.","45 Years",{"count":541,"type":22},111,[159],"The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight\u002Fobese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated",[545,26],"Overweight Subject",[547],"HDM1002","2025-12-30",{"date":550,"type":36},"2026-01-09",{"date":552,"type":36},"2025-09-24",{"date":554,"type":22},"2026-06-13",{"name":556,"class":171},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":44},"100615663","analysis-of-the-specificity-and-persistence-of-nasal-immune-responses-to-respiratory-viral-antigens-in-immunocompromised-and-healthy-cohorts-100615663","NCT07295535","Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts","Inclusion Criteria:\n\n* Informed Consent: Participants must have signed an informed consent form.\n* Age Range: Participants aged between 18 and 90 years.\n* Healthy Immunocompetent Donors: no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications.\n* Immunocompromised Patients: subjects with medical conditions or treatments associated with significant impairment of the immune system. This may include organ or stem cell transplants, ongoing immunosuppressive therapies, documented genetic immunosuppression.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Individuals unable to provide informed consent","90 Years",{"count":157,"type":22},"The goal of this observational study is to characterize nasal mucosal immunity to respiratory viruses, such as SARS-CoV-2, in immunocompromised individuals and healthy volunteers.\n\nThe study involves adults of any sex, between 18 and 90 years old, including both immunocompromised patients with medical conditions or treatments that can affect immune cell functions and healthy controls with no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications.\n\nResearchers will compare immunocompromised participants to healthy volunteers to determine how underlying immunodeficiency and related treatments affect immune cell composition and virus-specific responses.",[567,568,569,26,570],"Immuno-modulation","Immuno-suppression","Immunocompromised Patients","Oncological Patients","2025-12-16",{"date":573,"type":36},"2025-12-19",{"date":575,"type":36},"2025-09-01",{"date":577,"type":22},"2027-09-30",{"name":579,"class":101},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":52,"sex":587,"minAge":18,"maxAge":539,"enrollmentInfo":588,"targetDuration":4,"studyType":85,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":44},"100610010","phase-1-phase-1-study-of-intravaginal-kb15a-100610010","NCT07222020","Phase 1 Study of Intravaginal KB15A","Phase I, Placebo-Controlled, Double-Blinded, Randomized, Interventional, Safety and Pharmacokinetic Study of Single and Multiple Dosing of KB15A, a Vaginal Film Containing KB15A, an Anti-Sperm Monoclonal Antibody","Inclusion Criteria:\n\n* Age 18 to 45 years, inclusive\n* General good health (by volunteer history and per investigator judgment) without any clinically significant systemic disease (including, but not limited to significant liver disease\u002Fhepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes) and with an intact gastrointestinal tract, uterus and cervix.\n* History of regular menstrual cycles, by volunteer report, if not taking exogenous hormones\n* History of Pap smears and follow-up consistent with standard clinical practice as outlined in the Study Manual or willing to undergo a Pap smear at Visit 1\n* Willing to give voluntary consent and sign an informed consent form.\n* Willing to use non-spermicidal, lubricated condoms for any vaginal intercourse according to the study protocol.\n* Willing to abstain from intercourse and use of intravaginal medications, lubricants, and other products as required in the protocol.\n* Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection.\n* Must be protected from pregnancy by:\n\n  * Sterilization of either partner\n  * Heterosexual abstinence\n  * Hormonal contraceptives (except for the contraceptive vaginal ring)\n  * Copper IUD\n* If in a relationship, must be in a mutually monogamous relationship with a partner who is not known to be HIV positive and has no known risk of sexually transmitted infections (STIs)\n\nExclusion Criteria:\n\n* History of hysterectomy\n* Currently pregnant\n* Currently breastfeeding or planning to breastfeed during the course of the study\n* Current Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis,\n* Current symptomatic bacterial vaginosis (BV)\n* Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting\u002Fbleeding, discharge, etc.)\n* Significant gynecological abnormalities (including abnormal vaginal bleeding, excessive vaginal discharge, or vulvar\u002Fvaginal pain or irritation)\n* Current symptomatic UTI or vaginal candidiasis\n* History of sensitivity\u002Fallergy to KB15A film components, for either the volunteer\n* Less than 14 days since use of oral or vaginal antibiotics\n* Women with a history of genital herpes or condylomata who have been symptomatic in the last six months.\n* Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for an STI\n* Known current drug or alcohol abuse which could affect study compliance.\n* Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study\n* History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days\n* Abnormal finding on laboratory or physical examination or a social or medical condition in the participant, which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data.\n* Grade 2 or higher laboratory abnormality, per the 2014 update of the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events, or clinically significant laboratory abnormality as determined by the clinician.","FEMALE",{"count":589,"type":22},24,[159],"The goal of this clinical trial is to determine the safety and mucosal pharmacokinetics of KB15A, a vaginal film containing an anti-sperm monoclonal antibody, in healthy adult women. Researchers will compare KB15A use to placebo use, primarily to see if KB15A is associated with adverse events, and also to understand the local and systemic distribution of the KB15A monoclonal antibody following use of the vaginal film.\n\nParticipants will be assessed for the genital, mucosal and systemic safety and pharmacokinetics of KB15A in a preliminary single-dose phase of the study, where they will receive two single doses of either KB15A or placebo vaginal film, and again in a multiple-dose phase of the study, where they will receive 14 daily doses of either KB15A or placebo vaginal film.",[26],"2025-12-15",{"date":595,"type":36},"2025-12-17",{"date":597,"type":22},"2026-01-01",{"date":599,"type":22},"2026-12-28",{"name":601,"class":171},"ZabBio Inc.",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":609,"targetDuration":4,"studyType":85,"phases":610,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":44},"100616375","phase-1-this-is-a-phase-1-randomized-single-blind-placebo-controlled-study-to-assess-the-safety-pharmacokinetics-pk-and-pharmacodynamics-pd-of-beam-103-in-healthy-subjects-100616375","NCT07304791","This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects","A Randomized, Single-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BEAM-103 in Healthy Subjects","Inclusion Criteria:\n\n* Ages 18 to ≤55 years\n* Body mass index (BMI) of 18.5 to 25 kg\u002Fm2\n* Morning neutrophil count ≥2.6 × 109 cells\u002FL for Black\u002FAfrican American subjects or ≥3.5 ×109 cells\u002FL for Caucasian\u002FOther subjects\n* Baseline hemoglobin value of ≥14 g\u002FdL for males and ≥12 g\u002FdL for females\n* Baseline platelet count of \\>150 × 109\u002FL.\n* Subjects must be in general good health without significant medical conditions (based on physical exam, electrocardiogram (ECG), and laboratory test results with no clinically significant deviations), per the investigator's assessment\n\nExclusion Criteria:\n\n* Known hypersensitivity to any component of the investigational medicinal product (IMP).\n* Participation in another clinical trial involving treatment with an investigational agent within 90 days of informed consent is prohibited.\n* Positive serum pregnancy test or breastfeeding at screening (female participants).\n* Live virus vaccination within 4 weeks prior to signing informed consent.\n* Any severe or uncontrolled medical condition (eg. severe asthma or severe peanut allergy) that in the opinion of the investigator would put the subject at undue medical risk or impair the ability to interpret study results.",{"count":314,"type":22},[159],"The purpose of this Phase I single ascending dose study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BEAM-103 in healthy subjects between the ages of 18 and 55. The main questions the study aims to answer are:\n\n* Safety and tolerability of BEAM-103\n* The pharmacokinetic (PK) profile and pharmacodynamic (PD) characteristics of EAM-103\n* The effect of BEAM-103 on hematologic parameters\n* To assess the immunogenicity of BEAM-103\n\nResearchers will determine and establish the therapeutic window of the antibody and select optimal doses for future trials in patients.\n\nSubjects will:\n\n* Be asked to participate in the study for a duration of 4-5 months total\n* Be asked to sign informed consent\n* Be assessed for eligibility\n* Provide medical and medication history\n* Receive a single intravenous infusion of BEAM-103 or placebo on study Day 1 according to their assigned cohort\n* Be followed up to 4 months after infusion",[26,613],"Healthy Participant Study",[615,616],"ESCAPE","BEAM-103","2025-12-12",{"date":527,"type":36},{"date":620,"type":36},"2025-10-27",{"date":188,"type":22},{"name":623,"class":171},"Beam Therapeutics Inc."]